drugset / Trial / NCT02200237

A Clinical Study for Inactivated Vaccine Against EV71

NCT02200237

Phase 2 Completed 366 enrolled Medigen Vaccine Biologics Corp.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine in health children and infants aged from 2 months to \<12yrs.

Timeline

Start
2014-09
Primary completion
2017-05
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject EV71 vaccine Vaccine 150 ug